Edward Chan is a Principal at 1315 Capital, a Philadelphia-based firm that provides expansion and growth capital to healthcare companies. Prior to 1315 Capital, Mr. Chan was a vice president at NaviMed Capital, a lower middle-market healthcare investment firm and an associate at Siemens Venture Capital, the investment arm of Siemens. Mr. Chan also held an investment role at SAC Capital and a marketing role at Medtronic Cardiovascular. Mr. Chan started his career developing and commercializing a molecular diagnostic product at a venture-backed company.
Mr. Chan has been actively involved in the following investments: CenterPointe Behavioral Health System, Lucent Health Solutions, Genoptix (acquired by Neogenomics), China Diagnostics Medical Corporation (acquired by Actis Capital), BioImagene (acquired by Roche), RadPharm (acquired by JLL Partners), U-Systems (acquired by GE), MD Datacor (acquired by Noridian Mutual Insurance), Zonare (acquired by Mindray), Cylex (acquired by Viracor-IBT), and Sequenom (acquired by LabCorp). He currently serves on the boards of Centurion Service Group and Interpace Biosciences (NASDAQ:IDXG).
Mr. Chan received a BSc in Biomedical Engineering from Johns Hopkins University and an MBA from the Wharton School at the University of Pennsylvania.
Contact Edward at: [email protected]